Crossject

Crossject Days Inventory Outstanding

The Days Inventory Outstanding (DIO) of Crossject (ALCJ.PA) as of Oct 27, 2026 is 56.95. In the previous year, Days Inventory Outstanding (DIO) was 257.39 — a change of -77.87% (lower).

Days Inventory Outstanding

56.95

YoY

-77.87%

Last updated:

Days Inventory Outstanding (DIO) of Crossject is 2025 56.95 . Days Inventory Outstanding (DIO) of Crossject was 2024 257.39 . It decreases by -77.87% lower compared to the previous year.

The Crossject Days Inventory Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Inventory Outstanding
Date
Days Inventory Outstanding
Jan 1, 2018
187.33 EUR
Jan 1, 2019
53.21 EUR
Jan 1, 2020
140.94 EUR
Jan 1, 2021
50.63 EUR
Jan 1, 2022
49.26 EUR
Jan 1, 2023
61.84 EUR
Jan 1, 2024
257.39 EUR
Jan 1, 2025
56.95 EUR
The Crossject Days Inventory Outstanding history
YEARDays Inventory OutstandingYoY
56.95-77.87%
257.39+316.22%
61.84+25.53%
49.26-2.69%
50.63-64.08%
140.94+164.89%
53.21-71.60%
187.33-3.55%
194.22+127.99%
85.19-54.08%
185.52—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Crossject Stock analysis

What does Crossject do? Crossject SA is a company that specializes in the development and manufacturing of innovative drug delivery systems. The company was founded in 2006 by a team of professionals with the goal of changing the way medications are administered. Crossject's history began with the development of a unique drug delivery system called ZENEO. This system is based on a proprietary technology called "Needle Free Injection" that allows for needle-free and painless medication administration. The technology is safe, easy to use, and enables the administration of liquid medications and even solids in the form of suspensions. Crossject specializes in the application of this technology and develops products in various areas, including adrenaline for the treatment of life-threatening allergic reactions, methotrexate for the treatment of cancer, and anti-inflammatory medications for the treatment of asthma and COPD. The business model of Crossject is based on the development and commercialization of products based on the ZENEO technology. The company collaborates with a range of partners to bring its products to market, including pharmaceutical companies and other drug manufacturers. Crossject aims to sell its products worldwide and already has distribution partners in various countries around the world. Crossject is also committed to advancing the development of new products based on this technology. The company invests a significant portion of its revenue in research and development and works closely with academic institutions and other research facilities to improve its technology and products. Crossject's product offering includes a wide range of medications used for the treatment of various conditions. One example is the adrenaline injection system developed for the rapid and effective treatment of anaphylactic shocks that can occur as severe allergic reactions in people with food allergies, insect venom allergies, or drug allergies. The system does not require a needle and is therefore easy and safe to handle. Another example is the methotrexate injection for the treatment of cancer and autoimmune diseases such as rheumatoid arthritis and psoriasis. Crossject has also developed a range of products to combat asthma and chronic obstructive pulmonary disease (COPD). In 2019, the company received regulatory approval for its first commercial ZENEO product as an emergency treatment for migraines. This product is a fast-acting migraine therapy that is administered subcutaneously to quickly and effectively relieve pain and accompanying symptoms of migraines. In summary, Crossject is an innovative company specializing in the development and commercialization of drug delivery systems. The company utilizes a proprietary technology that allows for needle-free and painless medication administration and collaborates closely with partners to sell its products worldwide. Crossject continues to invest in research and development to bring new products based on its technology to market and establish itself as a leading company in its field. Crossject is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Crossject stock

Days Inventory Outstanding (DIO) of Crossject is 56.95 in 2025.

Days Inventory Outstanding (DIO) of Crossject changed from 257.39 to 56.95, representing a -77.87% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Days Inventory Outstanding (DIO) Crossject since 2006 – with annual values, charts, and detailed analysis.

DIO measures the average number of days inventory is held before being sold. Lower values indicate more efficient inventory management.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Inventory Outstanding (DIO)'s Crossject with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Inventory Outstanding (DIO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Inventory Outstanding (DIO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Crossject

All Key Metrics — Crossject